Edwin Asturias
Concepts (438)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Guatemala | 49 | 2023 | 296 | 4.310 |
Why?
| Microcephaly | 4 | 2023 | 54 | 2.910 |
Why?
| Vaccines | 6 | 2023 | 380 | 2.540 |
Why?
| Poliovirus Vaccine, Inactivated | 6 | 2018 | 25 | 2.430 |
Why?
| Rural Population | 14 | 2022 | 452 | 2.380 |
Why?
| Zika Virus Infection | 5 | 2022 | 85 | 2.320 |
Why?
| Poliomyelitis | 8 | 2018 | 30 | 2.180 |
Why?
| Vaccination | 14 | 2023 | 1222 | 2.110 |
Why?
| Poliovirus Vaccine, Oral | 7 | 2018 | 22 | 2.010 |
Why?
| Zika Virus | 4 | 2022 | 61 | 1.820 |
Why?
| Influenza, Human | 5 | 2022 | 554 | 1.770 |
Why?
| Infant | 38 | 2023 | 8293 | 1.650 |
Why?
| Child Development | 3 | 2022 | 410 | 1.350 |
Why?
| Viral Vaccines | 3 | 2018 | 90 | 1.340 |
Why?
| Caliciviridae Infections | 2 | 2018 | 17 | 1.250 |
Why?
| Norovirus | 2 | 2018 | 23 | 1.240 |
Why?
| Poliovirus | 6 | 2018 | 78 | 1.210 |
Why?
| Virus Shedding | 8 | 2017 | 41 | 1.190 |
Why?
| Haemophilus Vaccines | 5 | 2016 | 29 | 1.170 |
Why?
| Gastroenteritis | 2 | 2017 | 64 | 1.160 |
Why?
| Reminder Systems | 2 | 2019 | 163 | 1.100 |
Why?
| Text Messaging | 2 | 2019 | 155 | 1.060 |
Why?
| Growth Disorders | 2 | 2023 | 77 | 1.060 |
Why?
| Health Knowledge, Attitudes, Practice | 5 | 2023 | 1185 | 1.030 |
Why?
| Hepatitis B Vaccines | 4 | 2016 | 46 | 1.020 |
Why?
| Fever | 2 | 2017 | 283 | 1.010 |
Why?
| Immunization Schedule | 5 | 2017 | 188 | 0.960 |
Why?
| Streptococcal Vaccines | 1 | 2023 | 7 | 0.950 |
Why?
| Dengue Virus | 5 | 2022 | 31 | 0.900 |
Why?
| Child, Preschool | 23 | 2022 | 9491 | 0.900 |
Why?
| Immunization | 4 | 2023 | 412 | 0.890 |
Why?
| Meningitis, Meningococcal | 1 | 2022 | 5 | 0.890 |
Why?
| Neisseria meningitidis | 1 | 2022 | 19 | 0.890 |
Why?
| Meningococcal Infections | 1 | 2022 | 20 | 0.880 |
Why?
| Cell Phone | 3 | 2019 | 81 | 0.870 |
Why?
| Humans | 85 | 2023 | 118972 | 0.860 |
Why?
| Meningococcal Vaccines | 1 | 2022 | 49 | 0.850 |
Why?
| Dengue | 5 | 2022 | 60 | 0.850 |
Why?
| Streptococcal Infections | 1 | 2023 | 141 | 0.800 |
Why?
| Child | 22 | 2023 | 19129 | 0.790 |
Why?
| Antibodies, Neutralizing | 4 | 2017 | 228 | 0.780 |
Why?
| Pregnancy Complications, Infectious | 2 | 2022 | 296 | 0.760 |
Why?
| Rural Health Services | 2 | 2019 | 93 | 0.750 |
Why?
| Endpoint Determination | 1 | 2020 | 69 | 0.740 |
Why?
| Contraception | 4 | 2022 | 118 | 0.710 |
Why?
| Diphtheria-Tetanus-Pertussis Vaccine | 3 | 2016 | 25 | 0.710 |
Why?
| Diarrhea | 5 | 2023 | 181 | 0.700 |
Why?
| Immunity, Humoral | 3 | 2017 | 117 | 0.700 |
Why?
| Influenza Vaccines | 3 | 2021 | 500 | 0.690 |
Why?
| Patient Acceptance of Health Care | 3 | 2020 | 687 | 0.670 |
Why?
| Adolescent Health | 1 | 2019 | 39 | 0.670 |
Why?
| Immunity, Mucosal | 2 | 2016 | 86 | 0.660 |
Why?
| Arbovirus Infections | 1 | 2018 | 18 | 0.660 |
Why?
| Sentinel Surveillance | 2 | 2017 | 39 | 0.650 |
Why?
| Community Health Services | 2 | 2019 | 212 | 0.650 |
Why?
| Prospective Studies | 13 | 2023 | 6471 | 0.650 |
Why?
| Female | 47 | 2023 | 61564 | 0.650 |
Why?
| Haemophilus influenzae type b | 2 | 2014 | 11 | 0.640 |
Why?
| Carrier State | 3 | 2014 | 57 | 0.620 |
Why?
| Urban Health Services | 1 | 2017 | 60 | 0.610 |
Why?
| Immunogenicity, Vaccine | 1 | 2017 | 26 | 0.610 |
Why?
| Infant, Newborn | 13 | 2022 | 5255 | 0.600 |
Why?
| Consumer Product Safety | 1 | 2016 | 31 | 0.570 |
Why?
| Physician Assistants | 1 | 2017 | 68 | 0.560 |
Why?
| Neonatal Screening | 1 | 2017 | 152 | 0.560 |
Why?
| Community Health Planning | 1 | 2016 | 44 | 0.560 |
Why?
| Public-Private Sector Partnerships | 1 | 2016 | 43 | 0.560 |
Why?
| Parents | 3 | 2023 | 1212 | 0.550 |
Why?
| Family Planning Services | 3 | 2022 | 68 | 0.550 |
Why?
| Schools | 1 | 2019 | 411 | 0.540 |
Why?
| Population Health | 1 | 2016 | 46 | 0.540 |
Why?
| Anemia, Hemolytic | 1 | 2015 | 19 | 0.530 |
Why?
| Latin America | 5 | 2018 | 74 | 0.530 |
Why?
| Mobile Applications | 1 | 2017 | 147 | 0.530 |
Why?
| Post-Exposure Prophylaxis | 1 | 2014 | 6 | 0.520 |
Why?
| Caregivers | 1 | 2021 | 709 | 0.510 |
Why?
| Castleman Disease | 1 | 2014 | 14 | 0.510 |
Why?
| Haemophilus Infections | 1 | 2014 | 31 | 0.510 |
Why?
| Advisory Committees | 1 | 2016 | 212 | 0.510 |
Why?
| Needs Assessment | 2 | 2016 | 327 | 0.510 |
Why?
| Sexual Behavior | 1 | 2019 | 437 | 0.510 |
Why?
| Serogroup | 4 | 2018 | 34 | 0.500 |
Why?
| Exanthema | 1 | 2015 | 77 | 0.500 |
Why?
| Male | 36 | 2020 | 57801 | 0.500 |
Why?
| Herpes Zoster | 2 | 2015 | 336 | 0.490 |
Why?
| Population Surveillance | 1 | 2017 | 413 | 0.490 |
Why?
| Adolescent Behavior | 1 | 2019 | 482 | 0.480 |
Why?
| Brain Diseases | 1 | 2015 | 140 | 0.470 |
Why?
| Global Health | 1 | 2016 | 310 | 0.470 |
Why?
| Bacterial Capsules | 2 | 2014 | 32 | 0.470 |
Why?
| Calcitonin | 1 | 2013 | 29 | 0.470 |
Why?
| Receptors, Interleukin-6 | 1 | 2013 | 36 | 0.470 |
Why?
| Product Surveillance, Postmarketing | 1 | 2013 | 64 | 0.460 |
Why?
| Adverse Drug Reaction Reporting Systems | 1 | 2013 | 69 | 0.460 |
Why?
| Health Behavior | 1 | 2019 | 720 | 0.450 |
Why?
| Hospitalization | 7 | 2022 | 1785 | 0.450 |
Why?
| Antibodies, Bacterial | 2 | 2014 | 126 | 0.440 |
Why?
| Feces | 8 | 2018 | 396 | 0.440 |
Why?
| Protein Precursors | 1 | 2013 | 126 | 0.440 |
Why?
| Bacterial Infections | 2 | 2013 | 227 | 0.440 |
Why?
| Antibodies, Monoclonal, Humanized | 2 | 2014 | 667 | 0.430 |
Why?
| Pregnancy | 12 | 2022 | 5690 | 0.410 |
Why?
| Intestines | 4 | 2018 | 332 | 0.410 |
Why?
| Diet | 1 | 2019 | 1153 | 0.400 |
Why?
| Intestinal Mucosa | 1 | 2016 | 531 | 0.400 |
Why?
| Adolescent | 15 | 2019 | 18480 | 0.380 |
Why?
| Contraceptive Agents | 2 | 2021 | 57 | 0.370 |
Why?
| Surveys and Questionnaires | 5 | 2021 | 4708 | 0.360 |
Why?
| Saccharum | 3 | 2020 | 84 | 0.360 |
Why?
| Hepatitis B Antibodies | 1 | 2009 | 10 | 0.350 |
Why?
| Immunosuppressive Agents | 1 | 2013 | 681 | 0.350 |
Why?
| Adult | 22 | 2021 | 31512 | 0.340 |
Why?
| Antibodies, Viral | 7 | 2022 | 542 | 0.340 |
Why?
| Delivery, Obstetric | 2 | 2019 | 125 | 0.330 |
Why?
| Dengue Vaccines | 2 | 2018 | 9 | 0.330 |
Why?
| Young Adult | 11 | 2020 | 10793 | 0.330 |
Why?
| Multiplex Polymerase Chain Reaction | 2 | 2019 | 48 | 0.330 |
Why?
| Malnutrition | 1 | 2009 | 66 | 0.320 |
Why?
| Agriculture | 2 | 2020 | 90 | 0.320 |
Why?
| Urban Population | 3 | 2019 | 409 | 0.320 |
Why?
| World Health Organization | 3 | 2017 | 107 | 0.310 |
Why?
| Appointments and Schedules | 2 | 2019 | 78 | 0.310 |
Why?
| Cross-Sectional Studies | 5 | 2023 | 4552 | 0.300 |
Why?
| Primary Health Care | 1 | 2017 | 1560 | 0.300 |
Why?
| RNA, Viral | 2 | 2021 | 572 | 0.300 |
Why?
| Family Characteristics | 2 | 2018 | 156 | 0.300 |
Why?
| Acute Disease | 3 | 2019 | 940 | 0.290 |
Why?
| Seroconversion | 2 | 2017 | 48 | 0.290 |
Why?
| Glomerular Filtration Rate | 2 | 2020 | 683 | 0.270 |
Why?
| Viruses | 2 | 2023 | 96 | 0.260 |
Why?
| Anthropometry | 2 | 2022 | 194 | 0.250 |
Why?
| Streptococcus pneumoniae | 3 | 2016 | 141 | 0.250 |
Why?
| Vaccines, Conjugate | 2 | 2022 | 63 | 0.250 |
Why?
| Postpartum Period | 3 | 2022 | 271 | 0.250 |
Why?
| Meningitis, Haemophilus | 1 | 2003 | 6 | 0.240 |
Why?
| Culex | 1 | 2023 | 16 | 0.240 |
Why?
| Streptococcus pyogenes | 1 | 2023 | 35 | 0.230 |
Why?
| Pneumonia, Pneumococcal | 1 | 2003 | 40 | 0.230 |
Why?
| Aedes | 1 | 2023 | 53 | 0.230 |
Why?
| Cohort Studies | 4 | 2022 | 5116 | 0.230 |
Why?
| Psychometrics | 3 | 2021 | 631 | 0.230 |
Why?
| Biomarkers | 1 | 2013 | 3588 | 0.220 |
Why?
| Incidence | 4 | 2022 | 2424 | 0.220 |
Why?
| Postnatal Care | 2 | 2021 | 68 | 0.220 |
Why?
| Quality Improvement | 5 | 2022 | 963 | 0.220 |
Why?
| Immunization Programs | 2 | 2016 | 206 | 0.220 |
Why?
| Health Services Accessibility | 2 | 2020 | 781 | 0.220 |
Why?
| Anti-Infective Agents | 2 | 2020 | 227 | 0.220 |
Why?
| Vomiting | 1 | 2023 | 123 | 0.220 |
Why?
| Cough | 1 | 2023 | 102 | 0.220 |
Why?
| Travel | 3 | 2015 | 116 | 0.220 |
Why?
| Seroepidemiologic Studies | 2 | 2022 | 146 | 0.220 |
Why?
| Vital Signs | 1 | 2022 | 42 | 0.220 |
Why?
| Regression Analysis | 2 | 2022 | 983 | 0.210 |
Why?
| Meningitis, Bacterial | 2 | 2015 | 51 | 0.210 |
Why?
| Escherichia coli Vaccines | 2 | 2013 | 3 | 0.200 |
Why?
| Drug Therapy, Combination | 3 | 2016 | 965 | 0.200 |
Why?
| Herpesvirus 3, Human | 2 | 2015 | 389 | 0.200 |
Why?
| Cesarean Section | 2 | 2019 | 165 | 0.200 |
Why?
| Midwifery | 1 | 2022 | 41 | 0.200 |
Why?
| Attitude | 1 | 2023 | 231 | 0.200 |
Why?
| Health Promotion | 2 | 2019 | 691 | 0.200 |
Why?
| Malaria Vaccines | 1 | 2020 | 6 | 0.200 |
Why?
| Influenza A Virus, H3N2 Subtype | 1 | 2021 | 39 | 0.200 |
Why?
| Reproducibility of Results | 4 | 2021 | 2874 | 0.190 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 2 | 2013 | 245 | 0.190 |
Why?
| Yellow fever virus | 1 | 2020 | 3 | 0.190 |
Why?
| Birth Intervals | 1 | 2020 | 16 | 0.190 |
Why?
| Maternal Health Services | 1 | 2022 | 83 | 0.190 |
Why?
| Emergency Service, Hospital | 2 | 2022 | 1864 | 0.190 |
Why?
| Yellow Fever | 1 | 2020 | 7 | 0.190 |
Why?
| Immunologic Deficiency Syndromes | 2 | 2015 | 75 | 0.190 |
Why?
| Absenteeism | 1 | 2020 | 38 | 0.190 |
Why?
| Molecular Diagnostic Techniques | 1 | 2021 | 95 | 0.180 |
Why?
| Cesarean Section, Repeat | 1 | 2019 | 9 | 0.180 |
Why?
| Intensive Care, Neonatal | 1 | 2020 | 42 | 0.180 |
Why?
| Vaccination Refusal | 1 | 2020 | 69 | 0.180 |
Why?
| Vaginal Birth after Cesarean | 1 | 2019 | 21 | 0.180 |
Why?
| Contraception Behavior | 1 | 2020 | 81 | 0.180 |
Why?
| Agricultural Workers' Diseases | 1 | 2020 | 32 | 0.180 |
Why?
| Drug Discovery | 1 | 2020 | 124 | 0.180 |
Why?
| Language Tests | 1 | 2019 | 31 | 0.180 |
Why?
| Language Development Disorders | 1 | 2019 | 40 | 0.170 |
Why?
| Maternal Age | 1 | 2019 | 122 | 0.170 |
Why?
| Motor Skills | 1 | 2020 | 85 | 0.170 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 333 | 0.170 |
Why?
| Arboviruses | 1 | 2018 | 9 | 0.170 |
Why?
| Clinical Trials as Topic | 1 | 2023 | 969 | 0.170 |
Why?
| Seasons | 1 | 2021 | 461 | 0.170 |
Why?
| Community-Acquired Infections | 1 | 2020 | 143 | 0.170 |
Why?
| Thinness | 1 | 2019 | 91 | 0.160 |
Why?
| Puerto Rico | 1 | 2018 | 56 | 0.160 |
Why?
| Entamoeba histolytica | 1 | 2018 | 8 | 0.160 |
Why?
| Farmers | 1 | 2019 | 61 | 0.160 |
Why?
| Heat Stress Disorders | 1 | 2019 | 61 | 0.160 |
Why?
| Pregnancy in Adolescence | 1 | 2019 | 77 | 0.160 |
Why?
| Intensive Care Units, Neonatal | 1 | 2020 | 178 | 0.160 |
Why?
| Neoplasms | 2 | 2016 | 2179 | 0.160 |
Why?
| Mothers | 3 | 2022 | 682 | 0.160 |
Why?
| Chikungunya Fever | 1 | 2018 | 63 | 0.160 |
Why?
| Pregnant Women | 1 | 2019 | 132 | 0.160 |
Why?
| Treatment Refusal | 1 | 2018 | 86 | 0.160 |
Why?
| Vulnerable Populations | 1 | 2019 | 147 | 0.160 |
Why?
| Occupational Health | 2 | 2018 | 172 | 0.150 |
Why?
| Educational Status | 1 | 2019 | 437 | 0.150 |
Why?
| Child Health | 1 | 2019 | 137 | 0.150 |
Why?
| Vaccines, Attenuated | 1 | 2017 | 114 | 0.150 |
Why?
| Diagnostic Tests, Routine | 1 | 2018 | 88 | 0.150 |
Why?
| Health Surveys | 1 | 2019 | 454 | 0.150 |
Why?
| Pneumococcal Infections | 2 | 2016 | 96 | 0.150 |
Why?
| HIV Infections | 2 | 2014 | 2459 | 0.150 |
Why?
| Central Nervous System Viral Diseases | 1 | 2018 | 63 | 0.150 |
Why?
| Public Health | 2 | 2018 | 450 | 0.150 |
Why?
| Poliovirus Vaccines | 1 | 2016 | 3 | 0.150 |
Why?
| Child Behavior | 1 | 2019 | 212 | 0.150 |
Why?
| Databases, Factual | 3 | 2019 | 1231 | 0.150 |
Why?
| Myelitis | 1 | 2018 | 88 | 0.150 |
Why?
| Antigens, Viral | 1 | 2017 | 181 | 0.150 |
Why?
| Neuromuscular Diseases | 1 | 2018 | 90 | 0.140 |
Why?
| Panama | 1 | 2016 | 11 | 0.140 |
Why?
| Dominican Republic | 1 | 2016 | 20 | 0.140 |
Why?
| Colombia | 1 | 2016 | 43 | 0.140 |
Why?
| Vaccines, Combined | 2 | 2013 | 46 | 0.140 |
Why?
| Host-Pathogen Interactions | 1 | 2019 | 300 | 0.140 |
Why?
| Risk Factors | 7 | 2020 | 9000 | 0.140 |
Why?
| Peru | 1 | 2016 | 59 | 0.140 |
Why?
| Risk-Taking | 1 | 2019 | 319 | 0.140 |
Why?
| Occupational Exposure | 1 | 2019 | 277 | 0.140 |
Why?
| Sanitation | 1 | 2016 | 52 | 0.140 |
Why?
| Community Health Nursing | 1 | 2016 | 63 | 0.140 |
Why?
| Measles-Mumps-Rubella Vaccine | 1 | 2016 | 41 | 0.140 |
Why?
| Water Supply | 1 | 2016 | 71 | 0.140 |
Why?
| Anemia, Hemolytic, Autoimmune | 1 | 2015 | 14 | 0.140 |
Why?
| Rotavirus Vaccines | 1 | 2016 | 48 | 0.140 |
Why?
| Learning | 1 | 2020 | 374 | 0.140 |
Why?
| Health Services Needs and Demand | 1 | 2017 | 254 | 0.130 |
Why?
| Single-Blind Method | 1 | 2016 | 269 | 0.130 |
Why?
| Patient Preference | 1 | 2017 | 170 | 0.130 |
Why?
| Enterovirus Infections | 1 | 2018 | 164 | 0.130 |
Why?
| Typhoid Fever | 1 | 2015 | 10 | 0.130 |
Why?
| Chickenpox | 1 | 2016 | 100 | 0.130 |
Why?
| Community Participation | 1 | 2016 | 120 | 0.130 |
Why?
| Health Information Systems | 1 | 2015 | 18 | 0.130 |
Why?
| Analysis of Variance | 1 | 2018 | 1293 | 0.130 |
Why?
| Disease Outbreaks | 1 | 2018 | 322 | 0.130 |
Why?
| Education, Nursing | 1 | 2016 | 79 | 0.130 |
Why?
| Data Collection | 1 | 2018 | 658 | 0.130 |
Why?
| Overweight | 1 | 2019 | 502 | 0.130 |
Why?
| Antibody Affinity | 1 | 2014 | 55 | 0.130 |
Why?
| Biomedical Research | 1 | 2020 | 612 | 0.120 |
Why?
| Fatal Outcome | 1 | 2015 | 287 | 0.120 |
Why?
| Malaria | 1 | 2015 | 60 | 0.120 |
Why?
| Pleural Effusion | 1 | 2014 | 47 | 0.120 |
Why?
| Vincristine | 1 | 2014 | 99 | 0.120 |
Why?
| Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 82 | 0.120 |
Why?
| Cyclophosphamide | 1 | 2014 | 222 | 0.120 |
Why?
| Students | 1 | 2019 | 509 | 0.120 |
Why?
| History, 21st Century | 1 | 2014 | 170 | 0.120 |
Why?
| Severity of Illness Index | 2 | 2020 | 2674 | 0.120 |
Why?
| Mucocutaneous Lymph Node Syndrome | 1 | 2014 | 77 | 0.120 |
Why?
| Enterotoxins | 1 | 2013 | 86 | 0.120 |
Why?
| Colorado | 2 | 2020 | 4196 | 0.120 |
Why?
| Universities | 1 | 2016 | 347 | 0.120 |
Why?
| Calcitonin Gene-Related Peptide | 1 | 2013 | 33 | 0.120 |
Why?
| Rituximab | 1 | 2014 | 155 | 0.120 |
Why?
| Prednisone | 1 | 2014 | 235 | 0.120 |
Why?
| History, 20th Century | 1 | 2014 | 281 | 0.120 |
Why?
| Case-Control Studies | 1 | 2021 | 3171 | 0.120 |
Why?
| Renal Insufficiency, Chronic | 1 | 2020 | 589 | 0.120 |
Why?
| Socioeconomic Factors | 1 | 2017 | 1129 | 0.110 |
Why?
| Causality | 1 | 2013 | 109 | 0.110 |
Why?
| Bacterial Toxins | 1 | 2013 | 106 | 0.110 |
Why?
| Communicable Diseases | 1 | 2015 | 132 | 0.110 |
Why?
| Doxorubicin | 1 | 2014 | 302 | 0.110 |
Why?
| Health Policy | 1 | 2016 | 333 | 0.110 |
Why?
| Education, Medical | 1 | 2016 | 239 | 0.110 |
Why?
| Lymphocytes | 1 | 2014 | 347 | 0.110 |
Why?
| Delivery of Health Care | 1 | 2019 | 867 | 0.110 |
Why?
| Practice Guidelines as Topic | 1 | 2020 | 1440 | 0.110 |
Why?
| Gene Expression Profiling | 1 | 2019 | 1597 | 0.110 |
Why?
| Escherichia coli Proteins | 1 | 2013 | 170 | 0.110 |
Why?
| Acute Kidney Injury | 1 | 2019 | 709 | 0.100 |
Why?
| Aged, 80 and over | 1 | 2023 | 6561 | 0.100 |
Why?
| Lymph Nodes | 1 | 2014 | 455 | 0.100 |
Why?
| Program Evaluation | 1 | 2016 | 845 | 0.100 |
Why?
| Hypertension | 1 | 2020 | 1203 | 0.100 |
Why?
| Decision Support Systems, Clinical | 1 | 2013 | 178 | 0.100 |
Why?
| Kidney | 1 | 2018 | 1353 | 0.090 |
Why?
| Interleukin-6 | 1 | 2014 | 688 | 0.090 |
Why?
| Clinical Competence | 1 | 2017 | 951 | 0.090 |
Why?
| Immunization, Secondary | 1 | 2010 | 85 | 0.090 |
Why?
| Influenza A Virus, H1N1 Subtype | 1 | 2011 | 140 | 0.090 |
Why?
| Escherichia coli | 1 | 2013 | 758 | 0.090 |
Why?
| Physicians | 1 | 2017 | 794 | 0.080 |
Why?
| Penicillins | 1 | 2007 | 50 | 0.080 |
Why?
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2007 | 37 | 0.080 |
Why?
| Creatinine | 2 | 2020 | 491 | 0.080 |
Why?
| Nasopharynx | 1 | 2007 | 64 | 0.080 |
Why?
| Drug Resistance, Multiple, Bacterial | 1 | 2007 | 63 | 0.080 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 1390 | 0.070 |
Why?
| Cities | 2 | 2016 | 96 | 0.070 |
Why?
| Drug Administration Schedule | 1 | 2007 | 736 | 0.070 |
Why?
| Neuropsychological Tests | 2 | 2020 | 1032 | 0.060 |
Why?
| Mexico | 3 | 2013 | 165 | 0.060 |
Why?
| Tomography, X-Ray Computed | 1 | 2014 | 2436 | 0.060 |
Why?
| Sepsis | 2 | 2003 | 531 | 0.060 |
Why?
| Sensitivity and Specificity | 2 | 2020 | 1795 | 0.060 |
Why?
| Treatment Outcome | 4 | 2020 | 9342 | 0.060 |
Why?
| Haemophilus influenzae | 1 | 2003 | 50 | 0.060 |
Why?
| Mosquito Vectors | 1 | 2023 | 21 | 0.060 |
Why?
| Developing Countries | 2 | 2016 | 255 | 0.060 |
Why?
| Chickens | 1 | 2023 | 185 | 0.060 |
Why?
| Randomized Controlled Trials as Topic | 2 | 2019 | 1244 | 0.060 |
Why?
| Pandemics | 1 | 2011 | 1355 | 0.060 |
Why?
| Cross Reactions | 1 | 2022 | 116 | 0.050 |
Why?
| Longitudinal Studies | 2 | 2020 | 2513 | 0.050 |
Why?
| Middle Aged | 4 | 2017 | 27617 | 0.050 |
Why?
| Mammals | 1 | 2023 | 253 | 0.050 |
Why?
| Administration, Cutaneous | 2 | 2013 | 119 | 0.050 |
Why?
| Hospitals | 2 | 2016 | 598 | 0.050 |
Why?
| Paraguay | 1 | 2020 | 3 | 0.050 |
Why?
| Sri Lanka | 1 | 2020 | 12 | 0.050 |
Why?
| Endemic Diseases | 1 | 2020 | 28 | 0.050 |
Why?
| Reagent Kits, Diagnostic | 1 | 2020 | 42 | 0.050 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2022 | 827 | 0.050 |
Why?
| Translations | 1 | 2020 | 17 | 0.050 |
Why?
| Home Health Nursing | 1 | 2019 | 9 | 0.050 |
Why?
| Time Factors | 3 | 2019 | 6412 | 0.040 |
Why?
| Parity | 1 | 2019 | 101 | 0.040 |
Why?
| Specific Gravity | 1 | 2019 | 13 | 0.040 |
Why?
| Hospitals, Pediatric | 2 | 2015 | 505 | 0.040 |
Why?
| Child Language | 1 | 2019 | 22 | 0.040 |
Why?
| Feasibility Studies | 1 | 2022 | 749 | 0.040 |
Why?
| Prenatal Care | 1 | 2022 | 252 | 0.040 |
Why?
| Translating | 1 | 2019 | 35 | 0.040 |
Why?
| Electrolytes | 1 | 2019 | 59 | 0.040 |
Why?
| Rural Health | 1 | 2019 | 72 | 0.040 |
Why?
| Reproductive Health | 1 | 2019 | 68 | 0.040 |
Why?
| Parasites | 1 | 2019 | 40 | 0.040 |
Why?
| Infectious Disease Transmission, Vertical | 1 | 2020 | 156 | 0.040 |
Why?
| Dehydration | 1 | 2019 | 61 | 0.040 |
Why?
| Retrospective Studies | 4 | 2020 | 12978 | 0.040 |
Why?
| Culturally Competent Care | 1 | 2019 | 53 | 0.040 |
Why?
| Work Capacity Evaluation | 1 | 2018 | 13 | 0.040 |
Why?
| Bacteria | 2 | 2019 | 757 | 0.040 |
Why?
| Viral Load | 1 | 2020 | 419 | 0.040 |
Why?
| Coinfection | 1 | 2019 | 119 | 0.040 |
Why?
| House Calls | 1 | 2019 | 133 | 0.040 |
Why?
| Pregnancy Outcome | 1 | 2020 | 349 | 0.040 |
Why?
| Licensure | 1 | 2017 | 10 | 0.040 |
Why?
| Adjuvants, Immunologic | 1 | 2019 | 207 | 0.040 |
Why?
| Education, Medical, Continuing | 1 | 2019 | 125 | 0.040 |
Why?
| Chi-Square Distribution | 1 | 2019 | 525 | 0.040 |
Why?
| Chromatography, Affinity | 1 | 2017 | 85 | 0.040 |
Why?
| Epitope Mapping | 1 | 2017 | 49 | 0.040 |
Why?
| Choice Behavior | 1 | 2019 | 160 | 0.040 |
Why?
| Francisella | 1 | 1997 | 1 | 0.040 |
Why?
| Parenteral Nutrition | 1 | 1998 | 92 | 0.040 |
Why?
| Women's Health | 1 | 2019 | 274 | 0.040 |
Why?
| Counseling | 1 | 2020 | 353 | 0.040 |
Why?
| Paralysis | 1 | 2018 | 67 | 0.040 |
Why?
| Gastrointestinal Tract | 1 | 2019 | 175 | 0.040 |
Why?
| Gram-Negative Bacterial Infections | 1 | 1997 | 39 | 0.040 |
Why?
| Sequence Alignment | 1 | 2017 | 336 | 0.040 |
Why?
| Granulomatous Disease, Chronic | 1 | 1997 | 61 | 0.040 |
Why?
| Double-Blind Method | 2 | 2013 | 1687 | 0.040 |
Why?
| Enterovirus D, Human | 1 | 2018 | 76 | 0.040 |
Why?
| ROC Curve | 1 | 2017 | 473 | 0.030 |
Why?
| Chile | 1 | 2015 | 16 | 0.030 |
Why?
| Acyclovir | 1 | 2016 | 105 | 0.030 |
Why?
| Residence Characteristics | 1 | 2018 | 299 | 0.030 |
Why?
| IgG Deficiency | 2 | 2006 | 8 | 0.030 |
Why?
| IgA Deficiency | 2 | 2006 | 6 | 0.030 |
Why?
| Age Distribution | 1 | 2016 | 362 | 0.030 |
Why?
| Cholestasis | 1 | 1998 | 228 | 0.030 |
Why?
| Infusions, Intravenous | 1 | 2016 | 380 | 0.030 |
Why?
| Sex Distribution | 1 | 2016 | 351 | 0.030 |
Why?
| Spleen | 1 | 1997 | 510 | 0.030 |
Why?
| Computational Biology | 1 | 2019 | 588 | 0.030 |
Why?
| Healthy Volunteers | 1 | 2015 | 201 | 0.030 |
Why?
| Pneumococcal Vaccines | 1 | 2016 | 140 | 0.030 |
Why?
| Pedigree | 1 | 2015 | 485 | 0.030 |
Why?
| Blood Pressure | 1 | 2021 | 1664 | 0.030 |
Why?
| Maternal-Fetal Exchange | 1 | 2014 | 157 | 0.030 |
Why?
| Transcriptome | 1 | 2019 | 756 | 0.030 |
Why?
| Amino Acid Sequence | 1 | 2017 | 2071 | 0.030 |
Why?
| Europe | 1 | 2013 | 356 | 0.030 |
Why?
| Checklist | 1 | 2013 | 81 | 0.030 |
Why?
| Prevalence | 1 | 2019 | 2326 | 0.030 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 453 | 0.030 |
Why?
| Survival Rate | 1 | 2016 | 1720 | 0.030 |
Why?
| Adrenal Cortex Hormones | 1 | 2015 | 521 | 0.030 |
Why?
| Survival Analysis | 1 | 2015 | 1267 | 0.030 |
Why?
| Lymphocyte Activation | 1 | 2015 | 1067 | 0.030 |
Why?
| Oncology Service, Hospital | 1 | 2011 | 14 | 0.030 |
Why?
| Oseltamivir | 1 | 2011 | 11 | 0.030 |
Why?
| Comorbidity | 1 | 2016 | 1527 | 0.020 |
Why?
| Nuclear Proteins | 1 | 2015 | 597 | 0.020 |
Why?
| Antibodies, Monoclonal | 1 | 2017 | 1284 | 0.020 |
Why?
| Drug Delivery Systems | 1 | 2013 | 306 | 0.020 |
Why?
| Smoking | 1 | 2018 | 1487 | 0.020 |
Why?
| Body Mass Index | 1 | 2018 | 2092 | 0.020 |
Why?
| Anti-Bacterial Agents | 2 | 2011 | 1510 | 0.020 |
Why?
| El Salvador | 1 | 2010 | 7 | 0.020 |
Why?
| Animals | 2 | 2023 | 33381 | 0.020 |
Why?
| Latex Fixation Tests | 1 | 2008 | 3 | 0.020 |
Why?
| Brain Damage, Chronic | 1 | 2008 | 24 | 0.020 |
Why?
| Coma | 1 | 2008 | 32 | 0.020 |
Why?
| Leukocytosis | 1 | 2008 | 34 | 0.020 |
Why?
| DNA-Binding Proteins | 1 | 2015 | 1346 | 0.020 |
Why?
| Bacteriological Techniques | 1 | 2008 | 66 | 0.020 |
Why?
| Cerebrospinal Fluid | 1 | 2008 | 93 | 0.020 |
Why?
| Child Day Care Centers | 1 | 2007 | 34 | 0.020 |
Why?
| Cells, Cultured | 1 | 2015 | 4077 | 0.020 |
Why?
| Postoperative Complications | 1 | 1998 | 2235 | 0.020 |
Why?
| Shock | 1 | 2008 | 91 | 0.020 |
Why?
| Follow-Up Studies | 1 | 2016 | 4596 | 0.020 |
Why?
| Risk Assessment | 1 | 2016 | 3057 | 0.020 |
Why?
| Bacteremia | 1 | 2008 | 161 | 0.020 |
Why?
| Microbial Sensitivity Tests | 1 | 2007 | 302 | 0.020 |
Why?
| Ethiopia | 1 | 2006 | 35 | 0.020 |
Why?
| Pakistan | 1 | 2006 | 74 | 0.020 |
Why?
| Algorithms | 1 | 2013 | 1541 | 0.020 |
Why?
| Antiviral Agents | 1 | 2011 | 654 | 0.020 |
Why?
| Antineoplastic Agents | 1 | 2016 | 1974 | 0.020 |
Why?
| Ambulatory Care | 1 | 2007 | 482 | 0.010 |
Why?
| United States | 2 | 2015 | 12555 | 0.010 |
Why?
| Common Variable Immunodeficiency | 1 | 2004 | 27 | 0.010 |
Why?
| Agammaglobulinemia | 1 | 2004 | 32 | 0.010 |
Why?
| Brazil | 1 | 2004 | 109 | 0.010 |
Why?
| United Kingdom | 1 | 2004 | 236 | 0.010 |
Why?
| Confidence Intervals | 1 | 2004 | 324 | 0.010 |
Why?
| Short Bowel Syndrome | 1 | 1998 | 19 | 0.010 |
Why?
| Bilirubin | 1 | 1998 | 95 | 0.010 |
Why?
| Liver Failure | 1 | 1998 | 85 | 0.010 |
Why?
| Water Microbiology | 1 | 1997 | 78 | 0.010 |
Why?
| Abscess | 1 | 1997 | 75 | 0.010 |
Why?
| Aged | 1 | 2004 | 19657 | 0.000 |
Why?
|
|
Asturias's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|